Compare HNVR & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | NRXP |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 151.1M |
| IPO Year | 2022 | 2017 |
| Metric | HNVR | NRXP |
|---|---|---|
| Price | $26.66 | $3.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $24.50 | ★ $38.25 |
| AVG Volume (30 Days) | 25.5K | ★ 702.7K |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | $35.49 | $2,547.84 |
| Revenue Next Year | $8.61 | $1,591.73 |
| P/E Ratio | $34.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $1.65 |
| 52 Week High | $27.89 | $5.06 |
| Indicator | HNVR | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 60.49 | 46.05 |
| Support Level | $22.16 | $3.09 |
| Resistance Level | $27.89 | $3.50 |
| Average True Range (ATR) | 0.62 | 0.15 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 65.22 | 20.27 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.